Sugi Predict

Sugi Predict / Compounds / SCHEMBL1242355

SCHEMBL1242355

SCHEMBL1242355

CCCCCOc1ccc(-c2ccc(OC(F)(F)F)cc2)cc1NC(=O)C(=O)OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1I2 O75469 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MCHR1 Q99705 1/20 0.43
▸ PTPN11 Q06124 2/20 0.42
▸ GSK3B P49841 1/20 0.42
▸ KDR P35968 2/20 0.41
▸ HDAC3 O15379 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ EGFR P00533 1/20 0.41
▸ FGFR1 P11362 1/20 0.41
▸ FFAR1 O14842 2/20 0.40
▸ FFAR4 Q5NUL3 2/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ PTPN6 P29350 1/20 0.40
▸ VCP P55072 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ IDO1 P14902 1/20 0.40
▸ HRH2 P25021 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1241507 0.98 NR1I2 (0.45) NR1I2ALDH1A1SMN1; SMN2MCHR1GSK3B
SCHEMBL1241762 0.94 MCHR1 (0.45) NR1I2MCHR1GSK3BKDREGFR
SCHEMBL12890144 0.85 ABL1 (0.45) MCHR1KDREGFRFGFR1CYP2C9
SCHEMBL13581238 0.82 ABL1 (0.42) MCHR1PTPN11KDRFFAR4S1PR1
SCHEMBL1242849 0.82 ABL1 (0.46) MCHR1KDRFFAR1FFAR4S1PR1
SCHEMBL12952824 0.81 POLB (0.53) GSK3BHDAC1EGFRCYP2C9IDO1
SCHEMBL2533885 0.80 EPHX2 (0.47) NR1I2VCPCYP2C9IDO1
SCHEMBL2540485 0.79 EPHX2 (0.46) NR1I2VCPCYP2C9IDO1
SCHEMBL1239679 0.78 ABL1 (0.46) MCHR1KDR
SCHEMBL13581214 0.78 PTPN11 (0.54) NR1I2MCHR1PTPN11FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 — — US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 — — US disclosed
EP-2072498-A1 N-PHENYLOXAMIDIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-06-24 — — EP disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 NR1I2 1591/4885ALDH1A1 397/4885SMN1; SMN2 3040/4885
US-20090215899-A9 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 NR1I2 1591/4885ALDH1A1 397/4885SMN1; SMN2 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.